. . . . . . . . . . . . "Take with food to reduce gastric irritation."@en . . . . "m-Benzoylhydratropic acid"@en . . . . . . . . "Humans and other mammals"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. "@en . . . . "In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite."@en . . . . "For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain."@en . "3-Benzoylhydratropic acid"@en . . . "Conventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

"@en . "Avoid alcohol."@en . . . . . . . . "Ketoprofen"@en . "22071-15-4"@en . "approved"@en . . . . . "99% bound, primarily to albumin"@en . . . "L'Acide (benzoyl-3-phenyl)-2-propionique"@en . . "Orudis (tn)"@en . . "LD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

"@en . "Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. "@en . . . . . . . . "Ketoprofen"@en . . . . . . . . . . . . . "Attilio Citterio, Daniele Fancelli, \"Method of preparing ketoprofen.\" U.S. Patent US4845281, issued December, 1982."@en . . . . "Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours."@en . "2-(3-Benzoylphenyl)propionic acid"@en . . . "3-Benzoyl-\u03B1-methylbenzeneacetic acid"@en . . . . "* Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 \u00D7 50 mg)] * Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 \u00D7 200 mg)] * 0.08 L/kg/h * 0.7 L/kg/h [alcoholic cirrhosis patients]"@en . . "Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected. "@en . "# Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3526298 # Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16274258"@en . . . . . " "@en . . "3-Benzoyl-alpha-methylbenzeneacetic acid"@en . . .